TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07019675: A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of SKB518 in Patients With Lung Cancer

Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 192 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,596,200

Rescue Site Savings

+$7,669,200

Unlock Full NCT07019675 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07019675 Rescue Dossier →